{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:33:34Z","timestamp":1762810414813,"version":"build-2065373602"},"reference-count":30,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: To compare the former tuberculosis treatment regimen including one fluoroquinolone (ofloxacin, levofloxacin, or moxifloxacin) and a second-line injectable drug (amikacin, kanamycin, or capreomycin) plus three to five oral drugs (regimen 1) with the current regimen including the three WHO group A drugs (regimen 2) in terms of efficacy and safety at two tuberculosis referral centers in Mexico. Methods: This was a retrospective study based on a review of the clinical records of all consecutive rifampin-resistant or multidrug-resistant tuberculosis (RR\/MDR-TB) patients treated from January of 2010 to October of 2023. Patients included were microbiologically confirmed cases of RR\/MDR-TB with pulmonary involvement and who received at least 30 days of regimen 1 or regimen 2. Outcomes and adverse events were classified in accordance with WHO definitions. Results: One hundred and twenty-six RR\/MDR-TB patients met the inclusion criteria. Of those, 87 were treated with regimen 1 and 39 received regimen 2. Success rates were not significantly different between the two groups of patients, although those treated with the oral regimen including bedaquiline from regimen 2 had higher success rates. Regimen 2 patients experienced a shorter time to culture conversion, and the regimen length was shortened accordingly, the median duration being 16.1 months [IQR, 15-17.3 months]. In patients receiving the all-oral regimen 2, adverse events were significantly associated with a history of type 2 diabetes mellitus (OR = 15.4; 95% CI, 2.73-87.29; p = 0.002) and were mainly related to linezolid use. Conclusions: Oral regimens appear to be effective, although toxicity to linezolid requires strict patient monitoring.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20250131","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:30:54Z","timestamp":1762810254000},"page":"e20250131","source":"Crossref","is-referenced-by-count":0,"title":["Impact of new regimens and drugs on rifampin-resistant tuberculosis management in Mexico"],"prefix":"10.36416","author":[{"given":"Marcela","family":"Mu\u00f1oz-Torrico1","sequence":"first","affiliation":[{"name":"1. Cl\u00ednica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Laniado-Labor\u00edn2","sequence":"additional","affiliation":[{"name":"2. Facultad de Medicina y Psicolog\u00eda, Universidad Aut\u00f3noma de Baja California, Tijuana, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Rojas-Serrano3","sequence":"additional","affiliation":[{"name":"3. Departamento de Reumatolog\u00eda, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Becerril-Vargas4","sequence":"additional","affiliation":[{"name":"4. Laboratorio de Microbiolog\u00eda Cl\u00ednica, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Cinecio-Ch\u00e1vez2","sequence":"additional","affiliation":[{"name":"2. Facultad de Medicina y Psicolog\u00eda, Universidad Aut\u00f3noma de Baja California, Tijuana, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Leticia Luna-L\u00f3pez5","sequence":"additional","affiliation":[{"name":"5. Programa Nacional de Tuberculosis y Micobacteriosis, Centro Nacional de Prevenci\u00f3n y Control de Enfermedades - CENAPRECE - Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna","family":"-L\u00f3pez5","sequence":"additional","affiliation":[{"name":"5. Programa Nacional de Tuberculosis y Micobacteriosis, Centro Nacional de Prevenci\u00f3n y Control de Enfermedades - CENAPRECE - Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Armando Narvaez-D\u00edaz4","sequence":"additional","affiliation":[{"name":"4. Laboratorio de Microbiolog\u00eda Cl\u00ednica, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Renter\u00eda-Gamez2","sequence":"additional","affiliation":[{"name":"2. Facultad de Medicina y Psicolog\u00eda, Universidad Aut\u00f3noma de Baja California, Tijuana, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariela","family":"Segura del Pilar4","sequence":"additional","affiliation":[{"name":"4. Laboratorio de Microbiolog\u00eda Cl\u00ednica, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nallely","family":"Saavedra5","sequence":"additional","affiliation":[{"name":"5. Programa Nacional de Tuberculosis y Micobacteriosis, Centro Nacional de Prevenci\u00f3n y Control de Enfermedades - CENAPRECE - Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"C\u00e9sar Maga\u00f1a5","sequence":"additional","affiliation":[{"name":"5. Programa Nacional de Tuberculosis y Micobacteriosis, Centro Nacional de Prevenci\u00f3n y Control de Enfermedades - CENAPRECE - Ciudad de M\u00e9xico, M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"D\u2019Ambrosio6","sequence":"additional","affiliation":[{"name":"6. Public Health Consulting Group, Lugano, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Centis7","sequence":"additional","affiliation":[{"name":"7. Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Antonio Caminero8,9","sequence":"additional","affiliation":[{"name":"8. Servicio Neumolog\u00eda, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, Las Palmas, Espa\u00f1a. 9. Departamento de Actividades Cient\u00edficas, Alosa TB Academy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Battista Migliori7","sequence":"additional","affiliation":[{"name":"7. Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"ref0","unstructured":"1.           World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.           Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019;380(13):1201-1213. https:\/\/doi.org\/10.1056\/NEJMoa1811867","DOI":"10.1056\/nejmoa1811867"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.           World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.","DOI":"10.1186\/isrctn17334530"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.           Pontali E, Raviglione M. Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens? IJTLD Open. 2024;1(11):486-489. https:\/\/doi.org\/10.5588\/ijtldopen.24.0490","DOI":"10.5588\/ijtldopen.24.0490"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-834. https:\/\/doi.org\/10.1016\/S0140-6736(18)31644-1","DOI":"10.3410\/f.733954037.793565561"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.           World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.","DOI":"10.2471\/b09341"},{"key":"ref6","unstructured":"7.           World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Munoz-Torrico M, Salazar MA, Mill\u00e1n MJM, Mart\u00ednez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, et al. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. Eur Respir J. 2018;51(3):1702267. https:\/\/doi.org\/10.1183\/13993003.02267-2017","DOI":"10.1183\/13993003.02267-2017"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.           Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, et al. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Lancet Infect Dis. 2024;24(10):1151-1161. https:\/\/doi.org\/10.1016\/S1473-3099(24)00228-7","DOI":"10.1016\/s1473-3099(24)00228-7"},{"key":"ref9","unstructured":"10.        World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"ref10","unstructured":"11.        World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"ref11","unstructured":"12.        World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. Geneva: World Health Organization; 2016. WHO\/HTM\/TB\/2016.04"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.        Davis A, Meintjes G, Wilkinson RJ. Treatment of Tuberculous Meningitis and Its Complications in Adults. Curr Treat Options Neurol. 2018 Feb 28;20(3):5. https:\/\/doi.org\/10.1007\/s11940-018-0490-9","DOI":"10.1007\/s11940-018-0490-9"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.        Mu\u00f1oz-Torrico M, Caminero-Luna J, Migliori GB, D\u2019Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis. Arch Bronconeumol. 2017;53(5):245-250. https:\/\/doi.org\/10.1016\/j.arbres.2016.10.021","DOI":"10.1016\/j.arbr.2016.10.003"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.        Mu\u00f1oz-Torrico M, Caminero Luna J, Migliori GB, D\u2019Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. Rev Port Pneumol (2006). 2017;23(1):27-30. https:\/\/doi.org\/10.1016\/j.rppnen.2016.11.009","DOI":"10.1016\/j.rppnen.2016.11.009"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.        Santos AP, Benace CJ Jr, de Medeiros Leung JA, Kritski AL, de Queiroz Mello FC. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil - a real-world evidence study using a retrospective design. BMC Infect Dis. 2024;24(1):1112. https:\/\/doi.org\/10.1186\/s12879-024-09993-8","DOI":"10.1186\/s12879-024-09993-8"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.        Xu G, Hu X, Lian Y, Li X. Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):813. https:\/\/doi.org\/10.1186\/s12879-023-08765-0","DOI":"10.21203\/rs.3.rs-2251001\/v1"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.        Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810-823. https:\/\/doi.org\/10.1056\/NEJMoa2119430","DOI":"10.1056\/nejmoa2119430"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.        Hasan T, Medcalf E, Nyang\u2019wa BT, Egizi E, Berry C, Dodd M, et al. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Clin Infect Dis. 2024;78(3):730-741. https:\/\/doi.org\/10.1093\/cid\/ciad653","DOI":"10.1093\/cid\/ciad653"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.        Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M; IATDMCT Antimicrobial Scientific Committee. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Ther Drug Monit. 2020;42(1):83-92. https:\/\/doi.org\/10.1097\/FTD.0000000000000710","DOI":"10.1097\/ftd.0000000000000710"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.        Margineanu I, Akkerman O, Cattaneo D, Goletti D, Marriott DJE, Migliori GB, et al. Practices of therapeutic drug monitoring in tuberculosis: an international survey. Eur Respir J. 2022;59(4):2102787. https:\/\/doi.org\/10.1183\/13993003.02787-2021","DOI":"10.1183\/13993003.02787-2021"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.        World Health Organization. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.","DOI":"10.2471\/b09117"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.        Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, et al. Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis. EBioMedicine. 2015;2(11):1627-33. https:\/\/doi.org\/10.1016\/j.ebiom.2015.09.051","DOI":"10.1016\/j.ebiom.2015.09.051"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.        Cho Y, Park HS. Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea. BMJ Open. 2018 28;8(9):e020974. https:\/\/doi.org\/10.1136\/bmjopen-2017-020974","DOI":"10.1136\/bmjopen-2017-020974"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.        Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384. https:\/\/doi.org\/10.36416\/1806-3756\/e20210384","DOI":"10.36416\/1806-3756\/e20210384"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.        Ur Rehman O, Fatima E, Ali A, Akram U, Nashwan A, Yunus F. Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis. 2023;34:100405. https:\/\/doi.org\/10.1016\/j.jctube.2023.100405","DOI":"10.1016\/j.jctube.2023.100405"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.        Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D\u2019Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. https:\/\/doi.org\/10.1183\/13993003.00387-2017","DOI":"10.1183\/13993003.congress-2016.oa3518"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.        Dalcolmo M, Gayoso R, Sotgiu G, D\u2019Ambrosio L, Rocha JL, Borga L, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J. 2017;49(3):1602445. https:\/\/doi.org\/10.1183\/13993003.02445-2016","DOI":"10.1183\/13993003.02445-2016"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.        World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. Geneva: World Health Organization; 2024. https:\/\/doi.org\/10.2471\/B09123","DOI":"10.2471\/b09123"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.        Guglielmetti L, Khan U, Vel\u00e1squez GE, Gouillou M, Abubakirov A, Baudin E, et al. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med. 2025;392(5):468-482. https:\/\/doi.org\/10.1056\/NEJMoa2400327","DOI":"10.1056\/nejmoa2400327"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:30:55Z","timestamp":1762810255000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4164\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":30,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20250131","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]}}}